Half-dose neostigmine and low dose sugammadex as a reversal agent for vecuronium: A pilot randomized trial.
Zhe Chen, Lvdan Huang, Dongmei Dong et al.
✦ AI-curated · Sources linked
In 30 seconds
This pilot randomised trial compared reversal strategies for vecuronium-induced neuromuscular blockade in 80 patients undergoing elective urinary surgery under general anaesthesia. Patients received full-dose neostigmine, half-dose neostigmine followed by either 1.0 or 0.5 mg/kg sugammadex, or 2.0 mg/kg sugammadex. Recovery to a train-of-four ratio of at least 0.9 took 317.05 ± 55.04 s with half-dose neostigmine plus 1.0 mg/kg sugammadex and 361.68 ± 23.21 s with 0.5 mg/kg, versus 592.32 ± 159.88 s with full-dose neostigmine. Recovery times did not differ significantly from the 2.0 mg/kg sugammadex group.
Key findings
- Recovery times were 317.05 ± 55.04 s with half-dose neostigmine plus 1.0 mg/kg sugammadex and 361.68 ± 23.21 s with 0.5 mg/kg.
- Full-dose neostigmine recovery took 592.32 ± 159.88 s, significantly longer than in each sugammadex-containing group (P < 0.001).
- Recovery times did not differ significantly among the three sugammadex-containing regimens.
- One patient (5.3%) in the full-dose neostigmine group experienced hypoxia.
Why it matters
Residual neuromuscular blockade is a perioperative concern, and the trial suggests that combining half-dose neostigmine with lower-dose sugammadex can achieve recovery to a train-of-four ratio of at least 0.9 faster than full-dose neostigmine alone. The findings also provide comparative recovery-time data for these regimens, although they come from a pilot study in a specific surgical population.
What to keep in mind
This was a pilot trial with 80 patients undergoing elective urinary surgery; the abstract reports recovery times and hypoxia but does not establish broader clinical outcomes.